Vilamakitug not checked
XBiotech, Inc. · XB2001 · True Human IgG4 monoclonal antibody
FollowEvery change as it happens, and a Monday email
Trials
41 active
54 in total · 49 in the EU
Targets
—
None known yet
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-tug: unmodified immunoglobulins WHO name stem
- How it’s given
- “The active ingredient of Natrunix is an IgG4 monoclonal antibody indistinguishable from that naturally occurring in an IL-1a-immune healthy human. Natrunix is formulated as 200 mg/mL sterile liquid in a stabilizing isotonic formulation buffered to pH 7.0. The product is filled into a 2 mL glass pre-filled syringe suitable for subcutaneous injection. The drug product is formulated and buffered to…”In the company’s words, NCT06590090 on ClinicalTrials.gov
- Tested for
- Rheumatoid Arthritis, Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpA, Nr-axSpA
- Main trialPhase 2
- “Approximately 108 subjects will be randomized in 2 arms in 2:1 ratio to receive weekly subcutaneous injections of either 400mg Natrunix + MTX weekly or placebo + MTX weekly for 14 weeks. At the week 14 visit subjects in both arms will undergo a safety follow up visit OR begin receiving biweekly subcutaneous injections of 400mg Natrunix for 14 weeks as part of an Open Label Extension (OLE). The study will last for a maximum of 33 weeks, including: a screening period of up to 4 weeks, a 14-week double-blinded treatment phase followed by a 14-week open label extension phase and one-week…”In the company’s words, NCT06590090 on ClinicalTrials.gov
- Other names
- XB2001 · Natrunix · True Human IgG4 monoclonal antibody · methotrexate
Other drugs for Rheumatoid Arthritis
- TLL-018Hangzhou Highlightll Pharmaceutical Co., Ltd · Phase 3
- AdmilparantBristol Myers Squibb · Phase 3
- UpadacitinibAbbVie · Phase 3
- AbataceptBristol Myers Squibb · Phase 3
- AdalimumabAbbVie · Phase 3
- AnakinraSwedish Orphan Biovitrum · Phase 3
Coming up2
- 15 Jan 2027Phase 2 trial completes · ClinicalTrials.gov
- Sep 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials54
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 15 Jan 2027 | Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment | |
| Phase 2Not yet recruiting | Sep 2028 | Vilamakitug in Spondyloarthritis Placebo-controlled Investigation for Efficacy | |
| Phase 2Unknown | 15 Dec 2022 | Natrunix Versus Methotrexate in Rheumatoid Arthritis | |
| Phase 2Completed | 31 Oct 2024 | Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis | |
| Phase 1Completed | 8 Aug 2022 | Safety and Pharmacokinetics (PK) Study of Natrunix in Healthy Volunteers | |
| Phase 3Halted | not given | International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents | |
| Phase 2/3Authorised | not given | ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) with Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL) | |
| Phase 2Ended | not given | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy of Methotrexate as Remission Maintenance Therapy after Remission-Induction Therapy with Tocilizumab and Glucocorticoids in Subjects with Giant Cell Arteritis | |
| Phase 3Authorised | not given | An international prospective umbrella trial for children with atypical teratoid/rhabdoid tumours (ATRT) including a randomized phase III study evaluating the non-inferiority of three courses of high-dose chemotherapy (HDCT) compared to focal radiotherapy as consolidation therapy | |
| Phase 2Authorised | not given | Methotrexate treatment in hand osteoarthritis refractory to usual treatments: A randomised, double-blind, placebo-controlled trial, ADEM2 study | |
| Phase 3Ended | not given | HOVON 127 BL / SAKK 37/16: Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma | |
| Phase 3Authorised | not given | B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and adolescents | |
| Phase 2Authorised | not given | Hyper-CVAD/MA for high-risk aggressive B-cell lymphomas: a single-centre academic phase II trial (HYPERION) | |
| Phase 2Authorised | not given | A randomized trial comparing efficacy and safety of etanercept and methotrexate in giant cell arteritis (EFFECTA) | |
| Phase 4Authorised | not given | An international, multicentre, interventional, randomised assessor-blinded trial to MAXimise the METHotrexate therapy potential in patients with active rheumatoid arthritis (MethMax trial) | |
| Phase 3Authorised | not given | LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma | |
| Phase 2Authorised | not given | Randomized Phase 2 study testing two conditioning regimen with a single prophylaxis of graft-versus-host disease by cyclophosphamide and methotrexate post-transplant in patients eligible for matched-donor allograft transplantation _ CY-MET-RIC | |
| Phase 3Authorised | not given | A prospective, randomized, phase III open-label clinical trial with blinded ebd-point assessment to evaluate the efficacy and safety of cyclosporine and methoterxate in chlidren and adolescent subjects with moderate-to-severe atopic dermatitis. | |
| Phase 3Authorised | not given | AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia | |
| Phase 2Authorised | not given | An open-label single arm interventional phase 2 study to investigate outcome of individualized treatment based on pharmacogenomic profiling and ex vivo drug sensitivity testing of patient-derived organoids in patients with metastatic colorectal cancer | |
| Phase 2Ended | not given | Phase IIa Proof-of-Concept Study, with Dose-Titration Based on Treat-to-Target Strategy, to Investigate the Efficacy, Safety, and Tolerability of Subcutaneous Injection of Folate-based Liposomes Encapsulating Methotrexate (FBL-MTX) in Disease-modifying Antirheumatic Drugs (DMARD)-naïve Patients with Moderate-to-Severe Active Rheumatoid Arthritis and in Patients with an Inadequate Response or Intolerance to Oral MTX. | |
| Phase 2Authorised | not given | A Phase IIA Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin (IO) in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with positive Minimal Residual Disease before any Hematopoietic Stem Cell Transplantation. ALL2418 | |
| Phase 4Authorised | not given | The Methotrexate in ERosive INflammatory Osteoarthritis (MERINO) trial: A randomized placebo-controlled trial to investigate clinical efficacy and safety of methotrexate in erosive inflammatory hand osteoarthritis | |
| Phase 2Ended | not given | Randomized placebo-controlled trial comparing Methotrexate vs. Methotrexate/Metformin association in rheumatoid arthritis patients: METorMET² study. | |
| Phase 4Ended | not given | PeRsonalIzed MEdicine in Rheumatoid Arthritis (PRIMERA trial): a multicenter, open-label, randomized controlled trial comparing usual care with a tailor-made approach | |
| Phase 2/3Authorised | not given | SIOP Ependymoma Program II: An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependymoma | |
| Phase 3Ended | not given | MEthotrexate versus TOcilizumab for treatment of GIant cell Arteritis: a multicenter, randomized, controlled trial | |
| Phase 4Authorised | not given | Efficacy, tolerability and preferences of per oral or subcutaneous methotrexate in patients with early rheumatoid arthritis – a randomised register based multicentre study | |
| Phase 2/3Authorised | not given | LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis | |
| Phase 2Ended | not given | Efficacy and Tolerance of the Combination of Methotrexate and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo: a Randomized Doubleblind Prospective Study - METVI | |
| Phase 4Authorised | not given | Optimizing treatment for children and adolescents with Juvenile Idiopathic Arthritis in sustained remission: a comparison of three treatment strategies. An open randomized multicenter trial assessing two different treatment withdrawal strategies compared to continued stable treatment with methotrexate and tumor necrosis factor inhibitor in children and adolescents with juvenile idiopathic arthritis in stable remission. The MOVE-JIA trial | |
| Phase 3Ended | not given | CO-THEIA (COMBINATION THERAPY WITH METHOTREXATE AND ADALIMUMAB FOR UVEITIS): EFFICACY, SAFETY AND COST-EFFECTIVENESS OF METHOTREXATE, ADALIMUMAB, OR THEIR COMBINATION IN NON INFECTIOUS NON ANTERIOR UVEITIS: A MULTICENTER, RANDOMIZED, PARALLEL 3 ARMS, ACTIVE-CONTROLLED, PHASE 3 OPEN LABEL WITH BLINDED OUTCOME ASSESSMENT STUDY. | |
| Phase 2/3Authorised | not given | An International Prospective Study in Children Older than 3 to 5 Years with Clinically Standard-Risk Medulloblastoma with Low-Risk Biological Profile (PNET 5 MB – LR and PNET 5 MB – WNT-HR), average-risk biological profile (PNET 5 MB -SR), or TP53 mutation, and registry for MB ocurring in the context of genetic predisposition | |
| Phase 4Authorised | not given | The PREDMETH trial: Effectiveness of methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis - A randomized controlled trial | |
| Phase 4Authorised | not given | Toward personalized medicine to guide drug withdrawal in children with juvenile idiopathic arthritis in clinical remission: a randomized clinical trial comparing early versus late drug withdrawal combining imaging and multi-Omics. | |
| Phase 2Authorised | not given | SARCOME 13 / OS2016 - A Multicentre, Randomised, Open-label, Phase 2 trial of mifamurtide combined with post-operative chemotherapy for newly diagnosed high risk osteosarcoma patients (metastatic osteosarcoma at diagnosis or localised disease with poor histological response) | |
| Phase 2Ended | not given | A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy and safety of oral AP1189 administered at the doses of 40, 70, or 100 mg for 12 weeks in combination with methotrexate, in DMARD-naïve participants with early rheumatoid arthritis and active inflammation. | |
| Phase 3Authorised | not given | International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones | |
| Phase 3Authorised | not given | STOP-I-SEP_Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years | |
| Phase 3/4Authorised | not given | RANDOMIZED CONTROLLED CLINICAL TRIAL EVALUATING METHOTREXATE OR LEFLUNOMIDE + TARGETED THERAPY VERSUS METHOTREXATE OR LEFLUNOMIDE + SULFASALAZINE + HYDROXYCHLOROQUINE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INSUFFICIENT RESPONSE TO METHOTREXATE OR LEFLUNOMIDE (The BIO-3 trial) | |
| Phase 3Authorised | not given | TAWIS - Evaluation of TNF-alpha antagonists (Infliximab) withdrawal in sarcoidosis : a prospective, randomized, controlled trial. | |
| Phase 3Authorised | not given | Comparison of neurocognitive outcome in two standard regimen for treatment of low-risk medulloblastoma (COGNITO-MB) | |
| Phase 3Authorised | not given | Collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia. A randomized phase III study conducted in agreement with the AIEOP-BFM study group. | |
| Phase 2Authorised | not given | Phase II, multicentre, randomised, open-label trial with MAP +/- denosumab regimen for the treatment of patients with metastatic osteosarcoma | |
| Phase 2/3Authorised | not given | Ruxolitinib for childhood ALL in Poland (Rux-cALL-Pol 2020 trial) - Single-arm interventional study with ruxolitinib and AIEOP-BFM 2017 Poland or AIEOP-BFM 2017 standard of care chemotherapy in children with acute lymphoblastic leukemia and confirmed activation of JAK/STAT pathway. | |
| Phase 2Authorised | not given | ICC APL STUDY 02 Treatment study for children and adolescents with Acute Promyelocytic Leukemia | |
| Phase 2Authorised | not given | An interventional, open-label, Phase II study, to evaluate safety and efficacy of standard and high-dose chemotherapy associated with craniospinal irradiation in patients with metastatic medulloblastoma and other embryonal tumours | |
| Phase 2Authorised | not given | Chemoimmunotherapy in conjunction with blood-brain-barrier opening in patients with newly diagnosed or relapsed primary central nervous system lymphoma | |
| Phase 3Authorised | not given | AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia | |
| Phase 4Authorised | not given | Methotrexate in paediatric and adolescent Crohn’s disease: an observational study | |
| Phase 4Authorised | not given | MERCURE study: MEthotrexate in ReCurrent dVIN | |
| Phase 4Authorised | not given | Optimising Arthritis Strategies in Elderly patients (≥70 years) with rheumatoid arthritis in sustained low disease activity (the OASE study): A Prospective Target Trial Emulation Study Evaluating Tapering of Disease-Modifying Anti-Rheumatic Drugs vs. Usual Care Based on Patient Preference | |
| Phase 4Authorised | not given | DISCO-RA:DIScontinuation of COncomitant disease modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis patients also using TNF inhibitors - a randomized long-term non-inferiority strategy trial | |
| Phase 2Authorised | not given | A randomized, parallel-group, open-label, Phase IIb pilot trial to evaluate the effectiveness in reducing systemic disease activity with methotrexate compared with hydroxychloroquine in adult male and female participants with moderate-to-severe primary Sjögren’s disease (MOSAIC STUDY) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026